RTP Mobile Logo
Oncology Grand Rounds: Part 4 — Non-Small Cell Lung Cancer
Released July 2018

Video proceedings from the fourth in a series of 6 integrated symposia held at the 2018 ONS Annual Congress. Featuring perspectives from Dr Julie R Brahmer, Dr Jennifer Kapo, Ms Judy Pagtama, Dr Gregory J Riely and Ms Elizabeth S Waxman. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer (NSCLC).

    Lung cancer is a devastating disease with broad-reaching impact on public health, accounting for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In the year 2018, it is estimated that approximately 234,030 individuals will be diagnosed and more than 154,000 will die from the disease. Today, however, many have renewed optimism that these trends have already started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among scientists and clinicians working in this area of cancer medicine. Consequently, NSCLC currently represents one of the most rapidly evolving fields in oncology, as evidenced by a multitude of recent FDA approvals and the emergence of many pivotal data sets and novel agents potentially poised to disrupt traditional management algorithms.

    Although medical oncologists have been routinely responsible for counseling patients with regard to therapeutic decision-making, oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the fourth part of a 6-part integrated CNE curriculum originally held at the 2018 ONS Annual Congress feature discussions with leading lung cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with NSCLC.


    • Appreciate available research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with locally advanced, unresectable NSCLC.
    • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
    • Discuss the benefits and risks associated with evidence-based systemic treatments for metastatic NSCLC, including chemotherapeutic agents, targeted biologic therapies and immunotherapies.
    • Educate patients about the side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.
    • Assess emerging research on the benefits of early palliative care for patients with metastatic NSCLC, and integrate this information, as appropriate, into patient consultations.
    • Recall ongoing trials of other investigational approaches and agents in NSCLC, and refer patients and obtain consent for study participation.

    Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CNE credit is no longer available for this issue

    CNE credit is no longer available for this issue

    This is a video CNE program.
    CNE credit is no longer available for this issue

    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Julie R Brahmer, MD
    Director, Thoracic Oncology Program
    Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview
    Professor of Oncology
    Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins School of Medicine
    Baltimore, Maryland

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Merck; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company.

    Jennifer Kapo, MD
    Chief, Palliative Care Service
    Yale New Haven Hospital
    Associate Professor of Medicine
    Department of Internal Medicine
    Yale University School of Medicine
    New Haven, Connecticut

    No relevant conflicts of interest to disclose.

    Judy Pagtama, RN, MSN, FNP-C
    Nurse Practitioner
    Stanford Cancer Institute
    Palo Alto, California

    No relevant conflicts of interest to disclose.

    Gregory J Riely, MD, PhD
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Contracted Research: Genentech, Pfizer Inc, Takeda Oncology; Paid Travel: Merck; Other: AstraZeneca Pharmaceuticals LP.

    Elizabeth S Waxman, RN, MSN, ANP-BC
    Nurse Practitioner in the Department of Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME/CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Merck and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2018
    Expiration date: July 2019

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):